share_log

JP Morgan Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $48

Benzinga ·  Jul 25 22:08  · Ratings

JP Morgan analyst Brian Cheng maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $39 to $48.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment